Family Medicine Doctors in Snowflake, AZ Accepting Medicare
5 Family Medicine doctors found. Showing 1 - 5
 Alan N Dewitt, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 S Main St, Snowflake, AZ 85937 Phone: 928-536-7519 Fax: 928-536-7305 |
Larry W Nichols, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 S Main St, Snowflake, AZ 85937 Phone: 928-536-7519 Fax: 928-536-7305 |
Mark Lindsay, FNP-BC Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2601 N Mary Jane Ln, Snowflake, AZ 85937 Phone: 928-699-9643 |
Lawrence D Coss, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 S Main St, Snowflake, AZ 85937 Phone: 928-536-7519 Fax: 928-536-7305 |
Randal Jordan Shumway, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 S Main Street, Snowflake, AZ 85937 Phone: 928-536-7519 Fax: 928-532-2139 |
News Archive
New study heightens concerns over detrimental impact of air pollution on gene associated with AD risk
A new study by researchers at the Universities of Montana, Valle de México, Boise State, and North Carolina, the Centro de Ciencias de la Atmósfera, Universidad Nacional Autónoma de México, Instituto Nacional de Pediatría, and Centro Médico Cozumel heightens concerns over the detrimental impact of air pollution on hippocampal metabolites as early markers of neurodegeneration in young urbanites carrying an allele 4 of the apolipoprotein E gene (APOE).
Novel instrument may help limit spread of diarrhoea-causing bacteria
New strains of Clostridium difficile are making the diarrhoea-causing bacteria a global health problem. In hospitals especially, the bacteria can be extremely harmful. But a new instrument devised by Professor Chris Probert at The University of Bristol and Norman Ratcliffe from the University of the West of England (UWE) may help limit its spread.
FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials
Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.
Adding immunotherapy after initial treatment improves survival in metastatic NSCLC patients
Treating metastatic non-small cell lung cancer patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival compared to the historical average.
› Verified 2 days ago